Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Rubin Lab
Explore this Website
Home
News
About Us
Research
Lab Team
Publications
Resources
Toggle Resources menu options
FISH
Profiler
Tracking Samples
Weill Cornell Medicine
Care
Discover
Teach
Home
News
About Us
Research
Lab Team
Publications
Resources
Home
Publications
Publications
Found 13 results
Author
Title
Type
Year
Filters:
First Letter Of Title
is
E
[Clear All Filters]
2016
Barbieri CE
,
Chinnaiyan AM
,
Lerner SP
,
Swanton C
,
Rubin MA
. 2016.
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
.
Eur Urol.
Pauli C
,
Puca L
,
Mosquera JMiguel
,
Robinson BD
,
Beltran H
,
Rubin MA
,
Rao RA
. 2016.
An emerging role for cytopathology in precision oncology.
.
Cancer Cytopathol. 124(3):167-73.
2013
Lin P-C
,
Chiu Y-L
,
Banerjee S
,
Park K
,
Mosquera JMiguel
,
Giannopoulou E
,
Alves P
,
Tewari AK
,
Gerstein MB
,
Beltran H
et al.
. 2013.
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.
.
Cancer Res. 73(3):1232-44.
2012
Rubin MA
. 2012.
ETS rearrangements in prostate cancer.
.
Asian J Androl. 14(3):393-9.
Barbieri CE
,
Baca SC
,
Lawrence MS
,
Demichelis F
,
Blattner M
,
Theurillat J-P
,
White TA
,
Stojanov P
,
Van Allen E
,
Stransky N
et al.
. 2012.
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
.
Nat Genet. 44(6):685-9.
2010
Rickman DS
,
Chen Y-B
,
Banerjee S
,
Pan Y
,
Yu J
,
Vuong T
,
Perner S
,
Lafargue CJ
,
Mertz KD
,
Setlur SR
et al.
. 2010.
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.
.
Neoplasia. 12(12):1031-40.
Perner S
,
Svensson MA
,
Hossain RR
,
Day JR
,
Groskopf J
,
Slaughter RC
,
Jarleborn AR
,
Hofer MD
,
Kuefer R
,
Demichelis F
et al.
. 2010.
ERG rearrangement metastasis patterns in locally advanced prostate cancer.
.
Urology. 75(4):762-7.
2009
Tomlins SA
,
Bjartell A
,
Chinnaiyan AM
,
Jenster G
,
Nam RK
,
Rubin MA
,
Schalken JA
. 2009.
ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
.
Eur Urol. 56(2):275-86.
2008
Perner S
,
Wagner PL
,
Demichelis F
,
Mehra R
,
Lafargue CJ
,
Moss BJ
,
Arbogast S
,
Soltermann A
,
Weder W
,
Giordano TJ
et al.
. 2008.
EML4-ALK fusion lung cancer: a rare acquired event.
.
Neoplasia. 10(3):298-302.
Setlur SR
,
Mertz KD
,
Hoshida Y
,
Demichelis F
,
Lupien M
,
Perner S
,
Sboner A
,
Pawitan Y
,
Andrén O
,
Johnson LA
et al.
. 2008.
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
.
J Natl Cancer Inst. 100(11):815-25.
2005
Rubin MA
,
Allory Y
,
Molinié V
,
Leroy X
,
Faucon H
,
Vacherot F
,
Huang W
,
Kuten A
,
Salomon L
,
Rebillard X
et al.
. 2005.
Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome.
.
Urology. 66(5):930-4.
2004
Kumar-Sinha C
,
Shah RB
,
Laxman B
,
Tomlins SA
,
Harwood J
,
Schmitz W
,
Conzelmann E
,
Sanda MG
,
Wei JT
,
Rubin MA
et al.
. 2004.
Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
.
Am J Pathol. 164(3):787-93.
Hofer MD
,
Fecko A
,
Shen R
,
Setlur SR
,
Pienta KG
,
Tomlins SA
,
Chinnaiyan AM
,
Rubin MA
. 2004.
Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
.
Neoplasia. 6(5):503-12.